DUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) –Link here.
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation by Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short Course in San Diego, California on July 29, 2016. Frunevetmab (“NV-02”) is Nexvet’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy, which is being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in cats.
JVIM is a leading veterinary journal and the official publication of the American College of Veterinary Internal Medicine (ACVIM), the European College of Veterinary Internal Medicine, the European College of Veterinary Neurology, and the European College of Equine Internal Medicine.
The first paper, entitled “In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats” was published on the JVIM website on June 15, 2016 and details how Nexvet’s proprietary platform technology, PETization, was used to design the ‘100% cat’ frunevetmab, and also describes several early proof-of-concept studies.
The second paper, entitled “A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study” was published on the JVIM website on June 22, 2016 and focuses on a proof-of-concept study of frunevetmab in 34 cats. This study demonstrated long-lasting, statistically significant efficacy and informed the design of a further successful pilot study.
In May of 2016, Nexvet announced positive results from this larger pilot field study of frunevetmab. The study was a multi-center, placebo-controlled, randomized, double-blind field study conducted at 15 sites across the United States, and enrolled 126 cats with naturally occurring osteoarthritis. The study demonstrated statistically significant improvements over placebo on a range of endpoints and no significant adverse safety signals were observed. Nexvet is now preparing for a pivotal efficacy and field safety study of frunevetmab, anticipated to commence later in 2016.
Hyperlinks to the papers described above may be found on the frunevetmab page of Nexvet’s corporate website at www.nexvet.com.
“Nexvet is committed to scientific excellence, and part of building our leadership position in veterinary therapeutic biologic development is through sharing our strong scientific and clinical data with the wider veterinarian and clinical research community. We intend to continue building awareness of the clinical validation of PETization as a robust and rapid method for interspecies mAb translation, and the compelling advantages of biologics for the treatment of chronic conditions in companion animals,” said Dr. David Gearing, Chief Scientific Officer of Nexvet.
On a related matter, Nexvet is pleased to announce that Dr. Gearing will present a session on nerve growth factor as a target for controlling chronic pain in companion animals at the Veterinary Pain Short Course, which is a collaborative event hosted by UC San Diego’s School of Medicine, the International Veterinary Academy of Pain Management, and the American College of Veterinary Anesthesia and Analgesia.
About Nexvet (www.nexvet.com)
Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and conducts biomanufacturing in Ireland.
This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements consist of all statements other than statements of historical fact, including statements regarding our future results of operations and financial position, results of any current or future pivotal safety and efficacy study, future expenditures relating to our lead product candidates, time for completion of any of our studies or facilities upgrades, ability to develop our pipeline of product candidates, business strategy, prospective products, ability to successfully manufacture our own product candidates, ability to meet conditions for the receipt of government grants, time for regulatory submissions or ability to qualify for conditional licensure or obtain product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward looking statements. The words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “position,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. These forward looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. Factors that could cause actual results to differ materially from our expectations expressed in this report include those summarized under Risk Factors in our reports on Forms 10-Q and 10-K and the other documents we file from time to time with the Securities and Exchange Commission. Given these risks and uncertainties, you should not place undue reliance on these forward looking statements. Also, forward looking statements represent management’s beliefs and assumptions only as of the date of this press release. Except as required by law, we do not intend, and undertake no obligation, to revise or update these forward looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward looking statements, even if new information becomes available in the future.
Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 firstname.lastname@example.org Media Jessica Burns Berry & Company Public Relations +1 212-253-8881 email@example.com